Galectin Therapeutics Inc. (NASDAQ: GALT) Stock Information | RedChip

Galectin Therapeutics Inc. (NASDAQ: GALT) Listen to this Section


$2.17
-0.0850 ( -3.78% ) 27.3K

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Market Data


Open


$2.17

Previous close


$2.25

Volume


27.3K

Market cap


$138.59M

Day range


$2.13 - $2.28

52 week range


$1.47 - $4.27

Insider Ownership Transactions

Total Amount Purchased: -318,570.00 | $ -689,704.05

Date Type Amount Purchased Purchaser
2024-08-05 Sale -100000.00 Jamil Khurram
2024-07-23 Buy 400.00 ELDRED KARY
2024-06-20 Buy 2500.00 FREEMAN KEVIN D
2024-04-30 Buy 1000.00 Zordani Richard A. Jr.
2024-04-25 Sale -21323.00 CZIRR JAMES C
2024-04-25 Buy 1000.00 LEWIS JOEL
2024-04-22 Buy 2500.00 FREEMAN KEVIN D
2024-04-09 Sale -2063.00 FREEMAN KEVIN D
2024-03-04 Sale -152584.00 LEWIS JOEL
2024-02-07 Sale -50000.00 CARSON BENJAMIN SR

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 15 Aug 13, 2024
10-q Quarterly Reports 62 Aug 13, 2024
3 Insider transactions 2 Aug 05, 2024
4 Insider transactions 1 Aug 05, 2024
8-k 8K-related 16 Aug 01, 2024
4 Insider transactions 1 Jul 23, 2024
4/a Other 1 Jul 23, 2024
4 Insider transactions 1 Jun 20, 2024
8-k 8K-related 15 May 15, 2024
10-q Quarterly Reports 62 May 15, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.